Malignancy of the Reproductive Tract Flashcards
Origins of ovarian cancer
-Medulla
=Vasculature
=Loose stromal cells
-Epithelium
=Extension of the mesothelium which forms peritoneum
=Constant trauma, stimuli, turnover= more likely to be cancer
-Cortex
=Oocytes
=Granulosa cells
=Theca cells
=Fibroblasts
=Steroid cells
-Germ cell tumours
-Sex-cord stromal tumours
Cellular origins of ovarian cancer
-Endometrium/ retrograde menstruation
=Endometriosis
==Clear cell carcinoma
==Endometrioid carcinoma
-Fallopian tube epithelium
=High/ low grade serous carcinoma
-Ovarian surface epithelium
=High/ low grade serous carcinoma
=Relapse remitting, presents advanced (high)
=Presents earlier, poor response to chemo, slow turn over (low)
-Unknown
=Mucinous carcinoma
=Acts like GI cancer
Ovarian cancer subtypes
-High-grade serous carcinoma (70-74%)
=Most lethal
=Starts in fallopian tube- stick lesion in situ (neoplastic process)
-Clear cell carcinoma (10-26%)
-Endometrioid carcinoma (7-24%) best prognosis
-Low-grade serous carcinoma (3-5%)
-Mucinous carcinoma (2-6%)
-Carcinosarcoma (1-7%) tissues around cancer abnormal
-Other (0.6-7.1%)
Factors for increased risk of ovarian cancer
-ANYTHING THAT MAKES YOU OVULATE MORE
-Increased age
-FHx cancer
-Hereditary cancer syndrome
-Obesity?
-Having never given birth
-Hormone replacement therapy
-Increased numbers of lifetime ovulatory cycles
Factors for decreased risk of ovarian cancer
-Bilateral salpingo-oophorectomy
-Oophorectomy
-Bilateral salpingectomy with ovarian retention
-Hysterectomy
-Tubal ligation
-Use of oral contraceptives
-Breastfeeding
High-risk ovarian cancer susceptibility cancer syndromes with their associated suspected genes
-Hereditary breast and ovarian cancer syndrome (BRCA1/2- repairs breaks in DNA)
-Lynch syndrome (MLH1, MSH2/6, PMS2, EPCAM): common
-Li-Fraumeni syndrome (TP53- tumour suppression, guardian of the genome): rare
-Peutz-Jeghers syndrome (STK11/LKB1): petechiae on lip, bowel polyps
-Sex cord and mucinous tumours
Epidemiology and prognosis of Epithelial Ovarian Cancer (EOC)
-70% present with advanced disease (Stage III or IV)
-6th most common cancer among UK women(2014)
=Accounts for 4% of all new female cancer cases
-Highest mortality of all gynaecological cancers (resistant to chemo, advanced)
=36% of all women with EOC die within 1-year of diagnosis
-‘Silent Killer’
-Predominantly a post-menopausal disease
=Peak age 60-64 years
-Overall 5 year survival= 50%
=Stage 1: 90%, 2: 40%, 3: 20%, 4: 5%
Symptoms of EOC
-Present for >1 year and > 12 times per month:
=persistent abdominal distension (‘bloating’)
=early satiety and/or loss of appetite
=pelvic or abdominal pain
=increased urinary urgency and/or frequency
=unexplained weight loss
=fatigue
=abnormal uterine bleeding
OFTEN DIAGNOSED WITH IBS- suspect if diagnosed over 40
Protective factors in EOC
-COCP
-Pregnancy
-Sterilisation
-Hysterectomy
Risk factors in EOC
-Family History (BRCA)
=1 = 63%
=2 = 27%
-Null parity or 1st birth after 35
-Early menarche/late menopause
Investigation for EOC
-Bedside (urine dip, pregnancy, obs, BM), blood (FBC for platelets and anaemia of chronic disease, U&Es for renal function, LFT, clotting for invasive diagnostics, TFT for thyrotoxicosis), imaging (USS, CT staging, MRI, PET?), special test (tumour markers)
-CA-125 better for advanced cancers, raised in inflammation/ CA119 and CA15 for pancreatic and breast
=<40-years - AFP (especially germ cell) / BhCG / CA-125/ CEA marker of GI and lung to differentiate from ovarian
-USS Pelvis +/- TV
-CT CAP
-MDM
-RMI score = ultrasound score x menopausal score x CA125level in U/ml
-Screening?
RMI Score criteria
A. Menopausal status
=Pre (1)/ Post (3)
B. Ultrasonic features (1=1, >/2=3)
=Multiloculated
=Solid areas
=Bilaterality
=Ascites
C. Serum CA-125 titre absolute value
Tumour Size (7 cm)
Risk of malignancy index= A x B x C
=Cut off value 200 discriminates a benign from malignant mass with sensitivity 87% and specificity 97%
Diagnosis of EOC
-Tissue biopsy
=Laparoscopic with assessment of abdominal cavity
=Image guided
=Cytology not accepted alone (COVID-19)
-MDM discussion
=Gynae-oncology MDM
=Complex pelvic
Surgical management of EOC
-Aim: complete cytoreduction of all macroscopic disease (surgery beneficial in ovarian)
-Primary surgery is the standard of care where complete or optimal cytoreduction seems achievable in patients with good performance status
-Multi-visceral resection techniques such as peritoneal stripping, diaphragmatic resection, removal of bulky pelvic/ para-aortic lymph nodes, splenectomy and bowel resection.
-SCAN network – 55% of all patients undergo primary surgery (2017), 45%WOSCAN and 34% NCA.
EOC early disease treatment
-Staging laparotomy
=Peritoneal washings
=TAH/BSO
=Omentectomy
=Peritoneal biopsies
=Diaphragmatic biopsies
=Pelvic and bilateral para-aortic lymph node assessment up to the level of the insertion of the ovarian vessels in the absence of peritoneal dissemination
-Up to 30% of patients with apparently early stage disease will be upstaged after comprehensive staging
-Adjuvant platinum based chemotherapy offered in all cases except 1a/1b G1
EOC fertility sparing surgery
-Stage 1A
-Favourable histology
=Grade 1
=Grade 2 if non-clear cell
=Mucinous, serous, endometroid, or mixed histology
-In combination with appropriate staging
EOC advanced disease treatment
-Neo-adjuvant chemotherapy (before surgery)
=lower surgical mortality/ morbidity for unwell and significant comorbidity
=x3 cycles
-Interval imaging and MDM discussion
-Interval debulking surgery
-Baseline post-op imaging
-Adjuvant chemotherapy (carboplatin, paclitaxel x3 weekly for 6 cycles)- after surgery
-Anti-angiogenic (Bevacizumab)
EOC Follow up
-Variable ~ every 3 months for the first 2 years and then every 6 months
-Rises in CA125 to precede symptomatic relapse by a median of 4.5 months (range 0.5–29.5 months).
-No difference in OS between received chemotherapy for rising CA125 or until were symptomatic